Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies
Q Shi, C Xue, Y Zeng, X Yuan, Q Chu, S Jiang… - … and Targeted Therapy, 2024 - nature.com
Notch signaling, renowned for its role in regulating cell fate, organ development, and tissue
homeostasis across metazoans, is highly conserved throughout evolution. The Notch …
homeostasis across metazoans, is highly conserved throughout evolution. The Notch …
Exploiting innate immunity for cancer immunotherapy
M Yi, T Li, M Niu, Q Mei, B Zhao, Q Chu, Z Dai, K Wu - Molecular cancer, 2023 - Springer
Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …
However, most of these immunomodulatory strategies focus on harnessing adaptive …
Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance
R Ge, Z Wang, L Cheng - NPJ precision oncology, 2022 - nature.com
Prostate cancer is characterized by a high degree of heterogeneity, which poses a major
challenge to precision therapy and drug development. In this review, we discuss how …
challenge to precision therapy and drug development. In this review, we discuss how …
Uncovering the complex role of interferon-gamma in suppressing type 2 immunity to cancer
AA Bhat, A Goyal, R Thapa, I Kazmi, SI Alzarea… - Cytokine, 2023 - Elsevier
Cancer involves cells' abnormal growth and ability to invade or metastasize to different body
parts. Cancerous cells can divide uncontrollably and spread to other areas through the …
parts. Cancerous cells can divide uncontrollably and spread to other areas through the …
Radiomics in prostate cancer: An up-to-date review
M Ferro, O de Cobelli, G Musi… - Therapeutic …, 2022 - journals.sagepub.com
Prostate cancer (PCa) is the most common worldwide diagnosed malignancy in male
population. The diagnosis, the identification of aggressive disease, and the post-treatment …
population. The diagnosis, the identification of aggressive disease, and the post-treatment …
Using PSMA imaging for prognostication in localized and advanced prostate cancer
MJ Roberts, T Maurer, M Perera, M Eiber… - Nature Reviews …, 2023 - nature.com
The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, hel** to …
prostate cancer management has evolved rapidly over the past few years, hel** to …
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer
JE Hawley, AZ Obradovic, MC Dallos, EA Lim… - Cancer Cell, 2023 - cell.com
When compared to other malignancies, the tumor microenvironment (TME) of primary and
castration-resistant prostate cancer (CRPC) is relatively devoid of immune infiltrates. While …
castration-resistant prostate cancer (CRPC) is relatively devoid of immune infiltrates. While …
Nanotechnological approaches in prostate cancer therapy: integration of engineering and biology
M Ashrafizadeh, S Aghamiri, SC Tan, A Zarrabi… - Nano Today, 2022 - Elsevier
Nanocarriers have received special attention in biomedicine for the treatment of various
diseases, especially cancer, as one of the leading causes of death worldwide. Nanocarriers …
diseases, especially cancer, as one of the leading causes of death worldwide. Nanocarriers …
Phenotype switching and the melanoma microenvironment; impact on immunotherapy and drug resistance
SM Hossain, MR Eccles - International journal of molecular sciences, 2023 - mdpi.com
Melanoma, a highly heterogeneous tumor, is comprised of a functionally diverse spectrum of
cell phenotypes and subpopulations, including stromal cells in the tumor microenvironment …
cell phenotypes and subpopulations, including stromal cells in the tumor microenvironment …
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer
J Fernandez-Mateos, GD Cresswell, N Trahearn… - Nature Cancer, 2024 - nature.com
Cancer evolution lays the groundwork for predictive oncology. Testing evolutionary metrics
requires quantitative measurements in controlled clinical trials. We mapped genomic …
requires quantitative measurements in controlled clinical trials. We mapped genomic …